COVID-19 vaccine strategies must focus on severe disease and global equity.
作者信息
McIntyre Peter B, Aggarwal Rakesh, Jani Ilesh, Jawad Jaleela, Kochhar Sonali, MacDonald Noni, Madhi Shabir A, Mohsni Ezzeddine, Mulholland Kim, Neuzil Kathleen M, Nohynek Hanna, Olayinka Folake, Pitisuttithum Punnee, Pollard Andrew J, Cravioto Alejandro
机构信息
Department of Women's and Children's Health, University of Otago, Dunedin, New Zealand.
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
出版信息
Lancet. 2022 Jan 22;399(10322):406-410. doi: 10.1016/S0140-6736(21)02835-X. Epub 2021 Dec 16.
Abstract
摘要
相似文献
1
COVID-19 vaccine strategies must focus on severe disease and global equity.新冠病毒疫苗策略必须聚焦于重症疾病和全球公平性。
Lancet. 2022 Jan 22;399(10322):406-410. doi: 10.1016/S0140-6736(21)02835-X. Epub 2021 Dec 16.
2
Five priorities for universal COVID-19 vaccination.全球新冠病毒疫苗接种的五项优先事项。
Lancet. 2021 Jul 24;398(10297):285-286. doi: 10.1016/S0140-6736(21)01371-4. Epub 2021 Jun 18.
3
COVID-19 vaccinations: The unknowns, challenges, and hopes.COVID-19 疫苗接种：未知、挑战与希望。
J Med Virol. 2022 Apr;94(4):1336-1349. doi: 10.1002/jmv.27487. Epub 2021 Dec 10.
4
Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study.全球、区域和国家估计的 COVID-19 疫苗接种目标人群规模：描述性研究。
BMJ. 2020 Dec 15;371:m4704. doi: 10.1136/bmj.m4704.
5
SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.儿童人群中的 SARS-CoV-2 疫苗试验和研究：生物学、伦理、研究和实施挑战。
Pediatr Res. 2021 Nov;90(5):966-970. doi: 10.1038/s41390-021-01402-z. Epub 2021 Feb 24.
6
COVID-19: vaccination problems.新型冠状病毒肺炎：疫苗接种问题。
Environ Microbiol. 2021 Jun;23(6):2878-2890. doi: 10.1111/1462-2920.15549. Epub 2021 May 14.
7
Time-varying optimization of COVID-19 vaccine prioritization in the context of limited vaccination capacity.在有限的疫苗接种能力背景下，COVID-19 疫苗接种的时变优化。
Nat Commun. 2021 Aug 3;12(1):4673. doi: 10.1038/s41467-021-24872-5.
8
The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials.2019冠状病毒病疫苗试验中持续使用安慰剂的伦理问题
JAMA. 2021 Jan 19;325(3):219-220. doi: 10.1001/jama.2020.25053.
9
Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations.Ad26.COV2.S 疫苗与 BNT162b2 疫苗对 COVID-19 住院治疗的有效性。
JAMA Netw Open. 2022 Mar 1;5(3):e220868. doi: 10.1001/jamanetworkopen.2022.0868.
10
Equitable global access to coronavirus disease 2019 vaccines.2019冠状病毒病疫苗在全球的公平可及性。
BMJ. 2020 Dec 15;371:m4735. doi: 10.1136/bmj.m4735.
引用本文的文献
1
Comorbidity patterns associated with severe COVID-19 outcomes: A cohort study based on the UK Biobank.与严重新冠病毒病结局相关的共病模式：一项基于英国生物银行的队列研究。
PLoS One. 2025 Aug 22;20(8):e0329701. doi: 10.1371/journal.pone.0329701. eCollection 2025.
2
Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges.基于纳米平台的鼻腔内疫苗：当前进展和临床挑战。
ACS Nano. 2024 Sep 10;18(36):24650-24681. doi: 10.1021/acsnano.3c10797. Epub 2024 Aug 26.
3
Association of Prior COVID-19 Infection with Risk of Breakthrough Infection Following Vaccination: A Cohort Study in Isfahan, Iran.既往新冠病毒感染与疫苗接种后突破性感染风险的关联：伊朗伊斯法罕的一项队列研究
Int J Prev Med. 2024 Jul 17;15:18. doi: 10.4103/ijpvm.ijpvm_173_23. eCollection 2024.
4
Impact of the first year of COVID-19 vaccination strategy in Brazil: an ecological study.巴西 COVID-19 疫苗接种策略实施第一年的影响：一项生态学研究。
BMJ Open. 2024 Jul 4;14(7):e072314. doi: 10.1136/bmjopen-2023-072314.
5
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.提高免疫缺陷患者中针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）特异性免疫的策略概述
Vaccines (Basel). 2024 Jun 18;12(6):675. doi: 10.3390/vaccines12060675.
6
COVID-19 vaccine hesitancy among adults in India: A primary study based on health behavior theories and 5C psychological antecedents model.印度成年人对 COVID-19 疫苗的犹豫：基于健康行为理论和 5C 心理前因模型的初步研究。
PLoS One. 2024 May 9;19(5):e0294480. doi: 10.1371/journal.pone.0294480. eCollection 2024.
7
Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.摩洛哥卡萨布兰卡-塞塔特大区接种人群中 SARS-CoV-2 疫苗反应性及其相关因素的血清流行病学评估。
Sci Rep. 2024 Apr 3;14(1):7817. doi: 10.1038/s41598-024-58498-6.
8
Association of dietary inflammatory index and the SARS-CoV-2 infection incidence, severity and mortality of COVID-19: a systematic review and dose-response meta-analysis.膳食炎症指数与 SARS-CoV-2 感染 COVID-19 的发病率、严重程度和死亡率的关联：系统评价和剂量反应荟萃分析。
Nutr J. 2024 Feb 20;23(1):21. doi: 10.1186/s12937-024-00927-3.
9
Covid-19 vaccination coverage and associated factors among older hypertensive patients in Hangzhou, China.中国杭州老年高血压患者的新冠病毒疫苗接种率及相关因素
Int Health. 2025 Jan 3;17(1):62-70. doi: 10.1093/inthealth/ihae019.
10
Vaccines reduced hospital length of stay and fraction of inspired oxygen of COVID-19 patients: A retrospective cohort study.疫苗缩短了新冠患者的住院时长并降低了其吸氧比例：一项回顾性队列研究。
Prev Med Rep. 2024 Feb 1;39:102632. doi: 10.1016/j.pmedr.2024.102632. eCollection 2024 Mar.
本文引用的文献
1
Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant.完全接种疫苗的个体在感染 SARS-CoV-2 德尔塔变异株后免疫应答的特征。
Sci Transl Med. 2022 Apr 20;14(641):eabn6150. doi: 10.1126/scitranslmed.abn6150.
2
Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario.安大略省针对 COVID-19 疫苗对有症状的 SARS-CoV-2 感染和关注变种的严重后果的有效性。
Nat Microbiol. 2022 Mar;7(3):379-385. doi: 10.1038/s41564-021-01053-0. Epub 2022 Feb 7.
3
Vaccination strategies and transmission of COVID-19: Evidence across advanced countries.疫苗接种策略与 COVID-19 传播：先进国家的证据。
J Health Econ. 2022 Mar;82:102589. doi: 10.1016/j.jhealeco.2022.102589. Epub 2022 Jan 20.
4
Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study.2021 年 6 月至 7 月期间印度普通人群和医护人员中针对 SARS-CoV-2 的 IgG 抗体血清阳性率：一项基于人群的横断面研究。
PLoS Med. 2021 Dec 10;18(12):e1003877. doi: 10.1371/journal.pmed.1003877. eCollection 2021 Dec.
5
Booster Doses and Prioritizing Lives Saved.加强剂量与拯救生命的优先级
N Engl J Med. 2021 Dec 23;385(26):2476-2477. doi: 10.1056/NEJMe2117592. Epub 2021 Dec 8.
6
Aggressive containment, suppression, and mitigation of covid-19: lessons learnt from eight countries.积极管控、抑制和缓解 2019 冠状病毒病：八个国家的经验教训。
BMJ. 2021 Nov 28;375:e067508. doi: 10.1136/bmj-2021-067508.
7
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.英国未接种和接种疫苗人群中 SARS-CoV-2 德尔塔（B.1.617.2）变异株的社区传播和病毒载量动力学：一项前瞻性、纵向、队列研究。
Lancet Infect Dis. 2022 Feb;22(2):183-195. doi: 10.1016/S1473-3099(21)00648-4. Epub 2021 Oct 29.
8
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.BNT162b2 mRNA COVID-19 疫苗加强针在预防以色列重症结局的有效性：一项观察性研究。
Lancet. 2021 Dec 4;398(10316):2093-2100. doi: 10.1016/S0140-6736(21)02249-2. Epub 2021 Oct 29.
9
Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021.2021 年 8 月至 9 月，在德尔塔变异株（B.1.617.2）占主导地位期间，疫苗对向家庭接触者传播 SARS-CoV-2 的有效性，荷兰。
Euro Surveill. 2021 Nov;26(44). doi: 10.2807/1560-7917.ES.2021.26.44.2100977.
10
Effect of a nationwide booster vaccine rollout in Israel on SARS-CoV-2 infection and severe illness in young adults.以色列全国范围内开展加强疫苗接种对年轻成年人中新冠病毒感染及重症的影响。
Travel Med Infect Dis. 2021 Nov-Dec;44:102195. doi: 10.1016/j.tmaid.2021.102195. Epub 2021 Oct 30.
Zotero 插件